… chronic kidney disease, with or without type 2 diabetes, who were randomly assigned to
receive dapagliflozin … GFR of at least 50%, end-stage kidney disease, or death from renal or …

… trial, we show beneficial effects of dapagliflozin on kidney and cardiovascular end points in
… significant attenuation of loss of kidney function as reflected by the eGFR slopes over time. …

… of dapagliflozin on the prespecified kidney and cardiovascular outcomes in patients with
chronic kidney disease … of cardiovascular disease, in the DAPA-CKD trial (Dapagliflozin and …

… Among SGLT2is, dapagliflozin was the first to demonstrate the renoprotective effect in
patients with and without diabetes and has been approved for chronic kidney disease (CKD) …

… other trials in this field, the DAPA-CKD trial will provide unique insights into whether dapagliflozin
confers kidney protection in patients with CKD and diverse kidney disease aetiologies. …

… Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney
disease … The mean difference in eGFR slope between patients treated with dapagliflozin versus …

… Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study
assessed the efficacy and safety of dapagliflozin … 2 ; chronic kidney disease [CKD] stage 3A). …

… with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney,
… according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, …

… dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). …
Heart failure (HF) is common in patients with chronic kidney disease (CKD), reflecting the high …

… kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease
… did not affect proteinuria in patients with chronic kidney disease without diabetes, but did …